Epicur Pharma Receives FDA Warning Letter Over Misbranded Compounded Animal Drug Claims

Misbranding citations tied to promotional website content are now a documented enforcement vector for 503B outsourcing facilities, as Epicur Pharma's August 2026 warning letter from FDA's Center for Veterinary Medicine makes clear. The letter, addressed to CEO Michael Tursi of Stokes Healthcare Inc. dba Epicur Pharma, identifies product claims for compounded buprenorphine ER injection solution and omeprazole injection suspension as false or misleading under sections 502(a), 502(bb), and 201(n) of the FD&C Act.

FDA's core objection is that Epicur's website represented unapproved, non-indexed compounded animal drugs as comparable or superior to FDA-approved products without the evidentiary basis to support those comparisons. Promotional language including phrases such as "changing the game for equine gastric ulcers" and claims of faster healing rates drew specific scrutiny. The agency also challenged the cited clinical literature: the Sundra et al. 2024 study referenced to support a 10-day ESGD healing claim did not, per FDA's reading, evaluate treatment at that interval, did not return a statistically significant result for ESGD, and did not include a comparator arm using oral omeprazole drugs.

For QA directors and regulatory affairs leads at outsourcing facilities, the enforcement action reinforces a compliance boundary that is frequently underweighted: 21 CFR Part 530 and the FD&C Act's adequate directions for use provision apply to compounded animal drugs produced in 503B-registered human drug outsourcing facilities. Registration under section 503B does not exempt a facility from approval or indexing requirements, nor does it confer any implied equivalence with FDA-approved labeling. Compounded drugs using non-approved active ingredient sources remain outside the approval pathway regardless of facility registration status.

The misbranding findings here did not originate from a manufacturing inspection or a sterility failure, they arose from routine website review. That operational detail is relevant for facilities that maintain active digital marketing for compounded veterinary products: promotional content is subject to the same FD&C Act standards as labeling, and comparative efficacy or safety claims require the same evidentiary standard FDA applies to approved drug advertising.

FDA has requested that Epicur Pharma cease distribution of the misbranded products and provide a written response detailing corrective actions, with the agency reserving further regulatory action including injunction and seizure if violations continue.

Source: FDA Center for Veterinary Medicine via FDA.gov Warning Letters database, Warning Letter 733243, issued August 4, 2026; published September 29, 2026.